Spots Global Cancer Trial Database for Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Official Title: A Single-arm, Exploratory Clinical Study of Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Study ID: NCT05552651
Conditions
Study Description
Brief Summary: The objective is to investigate the efficacy and safety of envafolimab combined with chemotherapy for preoperative neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma
Detailed Description: This study is a single-arm, exploratory phase II clinical study. In the study, all patients with esophageal squamous cell carcinoma who meet the inclusion criteria will receive 3 cycles (21 days of 1 cycle) of neoadjuvant envolizumab combined with chemotherapy Treatment, radical surgery 4-6 weeks after completion of the last neoadjuvant therapy.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
